APOE3 Christchurch heterozygosity may delay cognitive impairment in Alzheimer’s disease
1. Carriers of the E280A variant of presenilin 1 (PSEN1E280A) who were heterozygous for the apolipoprotein E3 Christchurch variant (APOE3Ch) ...
Tag: Alzheimer’s
Eisai’s Leqembi wins accelerated U.S. approval and unlocks broader Medicare coverage for the drug
Leqembi reduced amyloid markers in early Alzheimer's disease and resulted in moderately less decline in measures of cognition and function ...
The 2 Minute Medicine Podcast Episode 35
Welcome to the 2 Minute Medicine Podcast, summarizing the latest medical studies, curated and written by practicing physicians. On this ...
The Scan by 2 Minute Medicine®: The Sound of Music, The Rise of a Promising Alzheimer’s Treatment, Pediatric Liver Transplant, A Heart-shaped Rash
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. ...
Gantenerumab does not slow cognitive decline in early Alzheimer’s
1. In these two randomized parallel-group trials, the use of gantenerumab did not lead to slower cognitive decline over 116 ...
Solanezumab does not slow cognitive decline in patients with Alzheimer’s disease
1. In this randomized controlled trial, over a period of 240 weeks, solanezumab did not slow cognitive decline as compared ...
The Scan by 2 Minute Medicine®: Battling Alzheimer’s, Bariatric Complications, Heat Wave Woes, and Not-So-Prime Energy Drinks
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. ...
Dementia is associated with high rates of sleep-related breathing disorders
1. In this meta-analysis, it was found that the pooled prevalence of sleep-related breathing disorders (SRBDs) among dementia patients was ...
Former professional football players may be at greater risk of chronic disease
1. In this retrospective cohort study, there was an increased prevalence of age-, race-, and body mass index (BMI)-adjusted cardiovascular, ...
Lecanemab may slow cognitive decline in early Alzheimer’s disease
1. Lecanemab was associated with reduced amyloid markers in early Alzheimer’s disease as compared to placebo. 2. Lecanemab also resulted ...
